AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More
ASTRAZENECA PHARMA | PFIZER | ASTRAZENECA PHARMA/ PFIZER |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 116.0 | 41.8 | 277.5% | View Chart |
P/BV | x | 35.5 | 6.9 | 511.6% | View Chart |
Dividend Yield | % | 0.0 | 0.5 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
PFIZER Mar-19 |
ASTRAZENECA PHARMA/ PFIZER |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 3,840 | 33.3% | |
Low | Rs | 883 | 2,080 | 42.4% | |
Sales per share (Unadj.) | Rs | 228.4 | 455.0 | 50.2% | |
Earnings per share (Unadj.) | Rs | 10.4 | 93.8 | 11.1% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 109.4 | 14.9% | |
Dividends per share (Unadj.) | Rs | 0 | 22.50 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.8 | 0.0% | |
Book value per share (Unadj.) | Rs | 98.8 | 658.2 | 15.0% | |
Shares outstanding (eoy) | m | 25.00 | 45.75 | 54.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 6.5 | 72.7% | |
Avg P/E ratio | x | 104.2 | 31.6 | 330.2% | |
P/CF ratio (eoy) | x | 66.4 | 27.1 | 245.5% | |
Price / Book Value ratio | x | 10.9 | 4.5 | 243.2% | |
Dividend payout | % | 0 | 24.0 | 0.0% | |
Avg Mkt Cap | Rs m | 27,008 | 135,420 | 19.9% | |
No. of employees | `000 | 1.4 | 2.6 | 51.5% | |
Total wages/salary | Rs m | 1,535 | 3,238 | 47.4% | |
Avg. sales/employee | Rs Th | 4,210.9 | 7,911.4 | 53.2% | |
Avg. wages/employee | Rs Th | 1,132.2 | 1,230.9 | 92.0% | |
Avg. net profit/employee | Rs Th | 191.1 | 1,630.7 | 11.7% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 20,815 | 27.4% | |
Other income | Rs m | 123 | 1,674 | 7.3% | |
Total revenues | Rs m | 5,833 | 22,489 | 25.9% | |
Gross profit | Rs m | 463 | 5,712 | 8.1% | |
Depreciation | Rs m | 147 | 714 | 20.6% | |
Interest | Rs m | 0 | 73 | 0.0% | |
Profit before tax | Rs m | 438 | 6,599 | 6.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 179 | 2,309 | 7.7% | |
Profit after tax | Rs m | 259 | 4,291 | 6.0% | |
Gross profit margin | % | 8.1 | 27.4 | 29.5% | |
Effective tax rate | % | 40.8 | 35.0 | 116.8% | |
Net profit margin | % | 4.5 | 20.6 | 22.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 27,167 | 11.8% | |
Current liabilities | Rs m | 2,070 | 8,917 | 23.2% | |
Net working cap to sales | % | 20.0 | 87.7 | 22.8% | |
Current ratio | x | 1.6 | 3.0 | 50.9% | |
Inventory Days | Days | 72 | 68 | 106.7% | |
Debtors Days | Days | 35 | 30 | 116.0% | |
Net fixed assets | Rs m | 790 | 8,862 | 8.9% | |
Share capital | Rs m | 50 | 458 | 10.9% | |
"Free" reserves | Rs m | 2,419 | 29,656 | 8.2% | |
Net worth | Rs m | 2,469 | 30,113 | 8.2% | |
Long term debt | Rs m | 0 | 25 | 0.0% | |
Total assets | Rs m | 4,605 | 39,400 | 11.7% | |
Interest coverage | x | NM | 91.5 | - | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.5 | 234.7% | |
Return on assets | % | 5.6 | 11.1 | 50.8% | |
Return on equity | % | 10.5 | 14.2 | 73.6% | |
Return on capital | % | 17.7 | 22.1 | 80.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 300 | 428 | 69.9% | |
Fx outflow | Rs m | 2,015 | 786 | 256.2% | |
Net fx | Rs m | -1,715 | -358 | 479.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 978 | 9.0% | |
From Investments | Rs m | -94 | 351 | -26.7% | |
From Financial Activity | Rs m | NA | -1,099 | 0.0% | |
Net Cashflow | Rs m | -6 | 231 | -2.5% |
Indian Promoters | % | 0.0 | 0.0 | - | |
Foreign collaborators | % | 75.0 | 63.9 | 117.4% | |
Indian inst/Mut Fund | % | 0.3 | 7.5 | 4.0% | |
FIIs | % | 15.7 | 4.9 | 320.4% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 23.7 | 38.4% | |
Shareholders | 12,856 | 85,207 | 15.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: SUN PHARMA PROCTER & GAMBLE HEALTH NOVARTIS FULFORD INDIA ORCHID PHARMA
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.
For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.
More Views on NewsIn this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.
A look at what India's top equity mutual funds bought and sold in January 2021.
More